Blog Post

EU trade in medical goods: why self-sufficiency is the wrong approach

As countries are struggling with the COVID-19 pandemic, shortages in medical equipment led to EU export controls and war-time like procurement of respirators. While the crisis is still unfolding, there is a debate on whether the EU is too reliant on global value chains for medical goods. Looking at the world market of medical goods for the EU, we argue that self-sufficiency is the wrong approach. Global medical markets are to the benefits of the EU and stockpiling and preparation are more effective in preparing for emergencies.

By: and Date: April 14, 2020 Topic: Global Economics & Governance

The European Union has enacted war-like procurement measures to counter shortages of personal protective equipment (PPE) during the COVID-19 crisis. Automotive and apparel companies are producing respirators and face masks, respectively. Meanwhile, countries are trying to prevent shortages of these goods, with Germany and France enacting export bans. The production of PPE in the EU is highly concentrated, with only the Czech Republic, France, Germany and Poland producing these goods on a large scale. To coordinate this response, the European Commission imposed EU-wide export controls. Questions are being asked about whether or not the EU should produce more of its own medical supplies beyond the current emergency procurement, and if it should reduce reliance on global supply chains. We argue that such measures should only be used in a limited way. As one of the largest producers of medical goods, the EU should avoid protectionism and should support global supply chains, with widespread research and production of medicine and medical equipment. Global markets for medical goods benefit the EU economically and also lead to knowledge sharing and specialisation that will help stem future epidemics. Stockpiling and preparation would have been a far more effective approach to prevent the shortages the EU is now experiencing, without any of the downside effects that domestic production requirements entail.

EU trade in medical goods

The EU is a net importer of COVID-19 related PPE. In 2019, it imported $17.6 billion worth of these goods and exported $12.1 billion. However, looking at the broader picture, the EU is one of the leaders in terms of trade in high-tech medical goods. Its share of global exports of such goods in 2017 was 29% – double the EU’s share of total global exports (15.2%). The EU is also a leading exporter of pharmaceutical goods and vaccines, representing nearly one third of world exports in both categories (Figure 1). For pharmaceutical goods, the EU tends to export standard products and import more advanced ones. This is related to the EU exporting many packaged medicines that are not considered high-tech (according to the United States Census Bureau), whereas the EU exports less high-tech vaccines. In medical equipment, the EU has a 26% share of world exports. In this category, its exports are more geared towards advanced goods, and its imports towards standard products (Figure 1  and Table 1).

In terms of EU trade in medical goods with its biggest partners, the US and China, there are major structural differences in the types of goods being traded. The EU and China sell one another similar shares of high-tech goods: around 40% of total medical goods trade between the two (Table 2). However, it is noticeable that the EU imports nearly no pharmaceutical goods from China, and that in exchanges of medical equipment, the EU tends to sell more advanced goods to China and import less technologically advanced goods. EU-US trade in medical goods is in gross value terms worth much more than the equivalent trade with China. The EU imports more high-tech medical goods from the US than it exports to the US (Table 3).

Buy local? 

As European governments experience shortages in procuring some medical goods, there are calls for an industrial policy that moves supply chains back to the EU. Emmanuel Macron wants “European and national sovereignty” and “full independence” in parts of the medical market. Some industry representatives go even further and call for “sanitary sovereignty”. We argue that such protectionist policies would hurt the EU more than it would gain. In parts of the market, local suppliers can be necessary to avoid shortages during an emergency, as currently. In these cases, domestic supply chains should be supported and protected. However, import-substitution policies should only be used carefully for specific products. The form the next epidemic will take is uncertain, while maintaining entire supply chains for a large number of products in the EU would be prohibitively expensive and could lead to major international tension. If the EU subsidised its pharmaceutical companies with the aim of moving entire supply chains of a larger number of goods into the EU, or required healthcare providers to procure medical goods only from EU suppliers, it would effectively close these markets to foreign producers. Some products, such as PPE, can be stockpiled, which makes domestic production less important. The question is more pressing for perishable medicines – goods for which the EU is already one of the largest exporters.

Global supply chains for non-high tech medicines support the development of pharmaceutical companies in emerging markets, leading to more research and skill spillovers, which will allow them to handle better the next pandemic. Modern medicine is highly complex, and there are substantial advantages from global sharing of research and development of drugs and equipment. This implies that there is also a substantial gain from global specialisation, instead of every country trying to cover every part of the medical goods market. Our trade data shows that as one of the most research-intensive regions in the world, the EU has a very strong position in this market. The EU is currently facing difficulties sourcing ‘low-technology’ medical supplies such as masks and protective equipment, but also more advanced products such as respirators. For the potential next stage of the pandemic, during which a vaccine should be administered to the population at mass scale, the situation might be more favourable to the EU because of its existing advantage in producing vaccines (the EU exports around 30% of all vaccines worldwide).

Therefore, we argue that while localisation of production for some specific goods might be necessary to prepare for pandemics, there are substantial advantages to keeping Europe’s markets for medical goods open. Therefore, the strategy should be targeted and should avoid protecting parts of the market where there is no need for local production. Healthcare in the EU already accounts for 10% of GDP, and these costs are likely to rise as Europe’s population continues to age. Production of goods in cheaper countries helps to manage these costs, and frees funds for other areas of healthcare, including pandemic preparation. Precautionary stockpiling of non-perishable medical goods and provision of intensive-care beds and medical testing facilities do not need local production, and would have gone a long way to alleviate the shortages currently experienced. A good example is Finland, where medical stockpiles help it to manage the current crisis. Stockpiling at European level, eg through rescEU and the European Civil Protection Mechanism, could create further efficiency gains and ensure that emergency supplies go to the regions most in need.


Republishing and referencing

Bruegel considers itself a public good and takes no institutional standpoint. Anyone is free to republish and/or quote this post without prior consent. Please provide a full reference, clearly stating Bruegel and the relevant author as the source, and include a prominent hyperlink to the original post.

Read article Download PDF More on this topic
 

Policy Contribution

The financial fragility of European households in the time of COVID-19

The concept of household financial fragility emerged in the United States after the 2007-2008 financial crisis. It grew out of the need to understand whether households’ lack of capacity to face shocks could itself become a source of financial instability.

By: Maria Demertzis, Marta Domínguez-Jiménez and Annamaria Lusardi Topic: European Macroeconomics & Governance Date: July 2, 2020
Read about event More on this topic
 

Upcoming Event

Jul
7
14:00

An EU budget for Europe's future with Johannes Hahn

How do we make the EU fit for future?

Speakers: Zsolt Darvas, Johannes Hahn and Mehreen Khan Topic: European Macroeconomics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels
Read about event More on this topic
 

Past Event

Past Event

Impact and additionality assessment in the time of COVID-19

Understanding the impact and additionality of policy interventions.

Speakers: Ugo Albertazzi, Benoit Campagne, Andrea Conte, Zsolt Darvas, Maria Demertzis, Francesco Di Comite, John Earle, Matteo Falagiarda, Áron Gereben, Helmut Kraemer-Eis, Hans Peter Lankes, Iana Liadze, Andrew McDowell, Nicola Pochettino, Debora Revoltella, Mattia Romani, Simone Signore, Natacha Valla, Georg Weiers and Marcin Wolski Topic: European Macroeconomics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 30, 2020
Read about event More on this topic
 

Past Event

Past Event

The need for market-based finance after COVID-19

How do COVID-19-caused financial dislocations inform policy responses?

Speakers: Maria Demertzis, Gabriel Makhlouf and Guntram B. Wolff Topic: Finance & Financial Regulation Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 29, 2020
Read article More on this topic More by this author
 

Podcast

Podcast

Redefining Europe’s role after the Covid-19 Pandemic

How will the Covid 19 crisis change the role of the EU in Europe and the world?

By: The Sound of Economics Topic: European Macroeconomics & Governance Date: June 25, 2020
Read about event More on this topic
 

Past Event

Past Event

Redefining Europe's role after the COVID-19 pandemic

Amidst COVID-19: how to keep markets integrated when states play a bigger role in the EU and its neighbourhood?

Speakers: Gabriele Bischoff, John Erik Fossum, Kalypso Nicolaïdis and Guntram B. Wolff Topic: European Macroeconomics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 25, 2020
Read about event More on this topic
 

Past Event

Past Event

COVID-19 in CEE and Europe’s neighbourhood: Do we need a Vienna Initiative 3.0?

How is the Vienna Initiative evolving to respond to the crisis caused by COVID-19?

Speakers: Thomas Wieser, Pierre Heilbronn, Mark Le Gros Allen, Piroska Nagy Mohacsi and Boris Vujčić Topic: European Macroeconomics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 24, 2020
Read article More on this topic More by this author
 

Opinion

A tale of two pandemics

The two narratives briefly examined here cast light on different aspects of the EU in the times of Covid-19. Euroskeptic nationalists typically propagate claims of EU failure but have been rather subdued during the pandemic as mainstream governments have taken over their trademark policy of closing borders to foreigners. Nonetheless, the grip on power of several pro-EU mainstream leaders, including President Emmanuel Macron in France, Prime Minister Conte in Italy and Prime Minister Pedro Sanchez in Spain, remains tenuous.

By: Michael Leigh Topic: European Macroeconomics & Governance Date: June 23, 2020
Read about event More on this topic
 

Past Event

Past Event

The role of AI in healthcare

How can AI help us fight through a pandemic crisis?

Speakers: Dimitris Bertsimas, Georgios Petropoulos, Effy Vayena and Reinhilde Veugelers Topic: Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 23, 2020
Read article Download PDF More by this author
 

Parliamentary Testimony

Italian Parliament

EU priorities and the recovery during Covid19

Testimony at the Committee on EU Policies of the Italian Chamber of Deputies.

By: Guntram B. Wolff Topic: European Macroeconomics & Governance, Italian Parliament, Testimonies Date: June 18, 2020
Read about event More on this topic
 

Past Event

Past Event

Biological threats and EU preparedness: How can we make the system more resilient?

Can the EU handle biological threats?

Speakers: Maria Demertzis, Magnus Normark, Ilkka Salmi, Jukka Savolainen, Anne Sénéquier and Reinhilde Veugelers Topic: Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 18, 2020
Read article More on this topic More by this author
 

Blog Post

The EU’s recovery fund proposals: crisis relief with massive redistribution

Poorer European Union countries and those hardest hit economically by the COVID-19 crisis could obtain up to 15% of their GNI in grants and guarantees from the EU’s proposed recovery instruments. Yet the proposal would represent a net benefit for all EU countries, even if there is only a small positive economic impact over the long-term. The proposed very long-maturity loans would lead to non-negligible benefits, exceeding 1% of GDP for some countries.

By: Zsolt Darvas Topic: European Macroeconomics & Governance Date: June 17, 2020
Load more posts